Analyst coverage

The following analysts evaluate the performance of Medacta stock and the investment opportunities for investors.
 

BERENBERG
Sam England, CFA

60 Threadneedle St
London EC2R 8HP
Phone: +44 20 34652687
sam.england@berenberg.com

MIRABAUD
Dr. Anja Pomrehn

29, Boulevard Georges-Favon
1204 Geneva
Phone: +41 44 7982468
anja.pomrehn@mirabaud-msl.com

MORGAN STANLEY
Aisyah Noor

25 Cabot Square, Canary Wharf
London E14 4QA
Phone: +44 20 7425-6177
aisyah.noor@morganstanley.com

OCTAVIAN AG
Ms. Sandra Dietschy, PhD

Hottingerstrasse 12
CH-8032 Zürich
Phone: +41 44 518 08 27
sandra.dietschy@octavian.ch

Research Partners AG
Mr. Alexander Burgansky, CFA

Hottingerstrasse 12
CH-8032 Zürich
Phone: +41 44 533 40 30
alexander.burgansky@researchpartners.ch

Stifel
Mr. Dylan van Haaften

150 Cheapside,
London EC2V 6ET
Phone: +44 (20) 7710 7462
dylan.vanhaaften@stifel.com

UBS
Mr. Graham Doyle

5 Broadgate
London EC2M 2QS
Phone: +44 20 7568 2587
graham.doyle@ubs.com

Zürcher Kantonalbank
Mr. Edouard Riva

Bahnhofstrasse 9
8010 Zurich
Phone: +41 44 292 20 05
edouard.riva@zkb.ch

Analysts' consensus

“The consensus forecast results from regular research reports prepared by analysts currently covering Medacta, as detailed in the «Analyst Coverage» section. The list of coverages has been drawn up to the best of Medacta’s knowledge but does not purport to be comprehensive of all institutions publishing financial research on Medacta. Any opinions, forecasts, estimates, projections or predictions regarding Medacta’s performance made by the analysts are exclusively theirs and do not represent opinions, forecasts, estimates, projections or predictions of Medacta’s management. The publication of this information on this website does not imply that Medacta endorses, or concurs with, the reports, conclusions or recommendations of the mentioned analysts. Medacta disclaims any liability for the accuracy or completeness of such information and does not assume any obligation to update it even if it becomes aware of any changes. This information is not an offer or solicitation to buy, hold or sell Medacta securities.”